Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

(2012) Roberto Iacovelli et al.   ACTA ONCOLOGICA

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

(2012) B. Markman et al.   ANNALS OF ONCOLOGY

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

(2012) Annett Mueller et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo

(2012) Hui Ren et al.   CANCER LETTERS

Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer

(2012) A.M. Gonzalez-Angulo et al.   CANCER TREATMENT REVIEWS

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors

(2012) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor

(2012) Patrizia Nanni et al.   PLoS One

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

(2011) Jose Pablo Maroto et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study

(2011) Neal E. Ready et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

(2011) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

(2011) Todd W. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma

(2010) Dorothy A. White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

(2010) C. O'Brien et al.   CLINICAL CANCER RESEARCH

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

Induction of Akt Activity by Chemotherapy Confers Acquired Resistance

(2009) Wei-Chien Huang et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

(2008) N. T. Ihle et al.   CANCER RESEARCH

Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia

(2008) M.-C. Crouthamel et al.   CLINICAL CANCER RESEARCH

Critical aspects of the Bayesian approach to phase I cancer trials

(2008) Beat Neuenschwander et al.   STATISTICS IN MEDICINE